SFM

Quote
anonymous said:
O7 will be hard. It didn't outperform maxalt alone at 2 hours... But that might not matter since pple cycle drugs like cray here
Click to expand...
I'm not so worried about this one. I spoke to the former godfather at Merck, the guy was employee 5 before the drug was approved and worked on it all the way through patent expiry. There are many ways to sell this.....take early, proximal absorption, focus on reduction of associated symptoms, 30 minute response, and rescue med for preventative mabs. Just focus on the Riza part.
 












anonymous said:
I'm not so worried about this one. I spoke to the former godfather at Merck, the guy was employee 5 before the drug was approved and worked on it all the way through patent expiry. There are many ways to sell this.....take early, proximal absorption, focus on reduction of associated symptoms, 30 minute response, and rescue med for preventative mabs. Just focus on the Riza part.
Click to expand...
Ridiculous. There are rescue mabs on the market. But anyone who knows wtf they’re talking about calls them anti-cgrp. Your guy is dated and giving you bad info. It’s a race out here to get through any step thru therapy (if there are any at all because the new drugs are that good) to get to what they want. That drug is going to fall flat and no one in there right mind would prescribe that old technology as a combo bs for a higher branded price. Absolutely insane that anyone would want to sell this.
 






anonymous said:
Ridiculous. There are rescue mabs on the market. But anyone who knows wtf they’re talking about calls them anti-cgrp. Your guy is dated and giving you bad info. It’s a race out here to get through any step thru therapy (if there are any at all because the new drugs are that good) to get to what they want. That drug is going to fall flat and no one in there right mind would prescribe that old technology as a combo bs for a higher branded price. Absolutely insane that anyone would want to sell this.
Click to expand...
The bottom line is that the drug doesn't work very well and doesn't have a compelling reason as to why anyone should use it. The data doesn't even support the its supposed value proposition very well. This drug will get completely drowned out by the branded CGRPs. It is a crappier version of treximet and will fail just as badly.
 
























anonymous said:
Couldn’t agree more. It’s gross! Obviously SFM is projecting onto the salesforce the sad truth about her life, money above all else, family, friends, colleagues and of course suffering patients. I would say she should be embarrassed, but that would imply that a narcissist is capable of human emotion.
Click to expand...
She is highlighting the top earners to provide talking points for the RBD’s forced to recruit anyone desperate enough and dumb enough to come to Axsome after reading this thread.
 


















anonymous said:
My sales are soaring because I'm a hustler baby. Look for me on Netflix Friday night. I'll be ringside at the Tyson fight with my customers!!
Click to expand...
Lost my wager and just signed over my fleet ride Nissan Rogue pink slip. I mean, the company is so dumb, I'm on the official title. Now to my point , I need a new fleet ride, how do I place an order? Are there any options besides the prissy gutless Rogue?
 












There is Inconsistent leadership and a lack of direction. No matter how good a drug might be if the company can’t get it on formularies it’s not going to be used because providers don’t have time to process prior auths with a million steps process. The company paid down co-pays to get HCPs using it and then quit without notice leaving patients and HCPs hanging, Reps are scrambling to pick up the pieces. It’s not surprising the company has been whistleblown on for shady specialty pharmacy crap, Do your research if you are thinking of working for them,
 


















anonymous said:
The bottom line is that the drug doesn't work very well and doesn't have a compelling reason as to why anyone should use it. The data doesn't even support the its supposed value proposition very well. This drug will get completely drowned out by the branded CGRPs. It is a crappier version of treximet and will fail just as badly.
Click to expand...
Are we talking psych or migraine?
 


















Top Bottom
Back
Quote